春立医疗(688236) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥257,113,202.13, representing a year-on-year increase of 13.45%[6] - Net profit attributable to shareholders was ¥74,021,366.53, reflecting an 8.09% increase compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥74,435,071.03, up by 10.05% year-on-year[6] - Total operating revenue for Q1 2022 was 257,113,202.13, an increase from 226,624,200.07 in Q1 2021, representing a growth of approximately 13.3%[32] - Net profit for Q1 2022 reached 74,021,366.53, compared to 68,481,917.59 in Q1 2021, reflecting a growth of approximately 8.5%[35] - The company reported a total comprehensive income of 74,021,366.53 for Q1 2022, compared to 68,481,917.59 in Q1 2021, reflecting an increase of approximately 8.5%[35] Research and Development - Research and development expenses totaled ¥33,114,231.75, marking a significant increase of 124.70%[9] - R&D expenses accounted for 12.88% of total revenue, an increase of 6.38 percentage points compared to the previous year[9] - Research and development expenses in Q1 2022 amounted to 33,114,231.75, significantly higher than 14,736,953.37 in Q1 2021, marking an increase of about 125%[32] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,040,149,651.90, a 1.35% increase from the end of the previous year[9] - Total current assets as of March 31, 2022, amounted to approximately CNY 2.48 billion, an increase from CNY 2.45 billion as of December 31, 2021, reflecting a growth of about 1%[24] - Total assets reached CNY 3.04 billion, up from CNY 2.99 billion, indicating an increase of approximately 1%[27] - Total liabilities included accounts payable of CNY 100.62 million, down from CNY 142.42 million, a decrease of about 29%[27] - Total liabilities decreased from 530,579,974.97 to 497,050,898.89, a reduction of approximately 6.3%[29] - Total equity attributable to shareholders increased from 2,469,077,386.48 to 2,543,098,753.01, representing a growth of about 3%[29] Cash Flow - The net cash flow from operating activities was -¥20,120,816.00, a decline of 290.44% compared to the same period last year[6] - In Q1 2022, the cash inflow from operating activities was CNY 209,155,705.21, an increase from CNY 187,095,545.12 in Q1 2021, representing an increase of approximately 11.0%[37] - The net cash outflow from operating activities in Q1 2022 was CNY -20,120,816.00, compared to a net inflow of CNY 10,565,240.29 in Q1 2021[37] - The total cash outflow from operating activities in Q1 2022 was CNY 229,276,521.21, compared to CNY 176,530,304.83 in Q1 2021, reflecting an increase of approximately 29.8%[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,622[16] - The company reported a basic earnings per share of ¥0.19, down by 5.00% year-on-year[9] - Earnings per share for Q1 2022 were 0.19, slightly down from 0.20 in Q1 2021[35] Other Financial Metrics - The weighted average return on equity was 2.95%, a decrease of 3.20 percentage points year-on-year[9] - Cash and cash equivalents decreased to CNY 1.03 billion from CNY 1.74 billion, representing a decline of approximately 41%[24] - Accounts receivable increased to CNY 494.51 million from CNY 400.19 million, showing a growth of about 23%[24] - The company’s inventory decreased to CNY 155.36 million from CNY 159.68 million, a decline of approximately 3%[24] - The company’s other receivables increased to CNY 5.49 million from CNY 4.49 million, showing a growth of about 23%[24] - The company reported a decrease in employee compensation payable to CNY 25.02 million from CNY 46.27 million, a reduction of approximately 46%[27] - The company’s non-current assets totaled CNY 562.68 million, slightly up from CNY 551.89 million, reflecting an increase of about 2%[27] - Deferred income tax liabilities decreased from 5,402,815.13 to 5,210,334.06, a decline of approximately 3.5%[29] - The impact of exchange rate changes on cash and cash equivalents in Q1 2022 was CNY -218,020.84, contrasting with a positive impact of CNY 43,992.26 in Q1 2021[39] - The cash inflow from investment activities in Q1 2022 was CNY 904,215.33, down from CNY 2,203,041.10 in Q1 2021, a decrease of approximately 58.9%[39] - The net cash outflow from investment activities in Q1 2022 was CNY -690,328,193.10, compared to CNY -50,448,583.11 in Q1 2021, indicating a significant increase in outflows[39]